ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL

被引:17
作者
Shteper, PJ
Siegfried, Z
Asimakopoulos, FA
Palumbo, GA
Rachmilewitz, EA
Ben-Neriah, Y
Ben-Yehuda, D
机构
[1] Hadassah Univ Hosp, Dept Hematol, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91010 Jerusalem, Israel
[3] Univ Catania, Dept Hematol, Catania, Italy
基金
以色列科学基金会;
关键词
acute lymphoblastic leukemia; chronic myeloid leukemia; Philadelphia chromosome; ABL; methylation;
D O I
10.1038/sj.leu.2402026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In human Ph-positive leukemia there is a clear association of different forms of the BCR-ABL oncogene with distinct types of leukemia. The P190 form of BCR-ABL is rarely observed in chronic myeloid leukemia (CML) but is present in 50% of Ph-positive acute lymphoblastic leukemia (ALL). In contrast, the P210 form is observed both in CML and 50% of Ph-positive ALL. Methylation of the proximal promoter of the ABL1 gene has been shown to he a nearly universal event associated with clinical progression of CML. This raises the question of whether methylation of the ABL1 promoter is an epigenetic modification also associated with Ph-positive ALL. To study this issue, we used methylation-specific PCR and bisulfite sequencing to determine the methylation status of the ABL1 promoter in 18 Ph-positive ALL samples. We report here that gene-specific ABL1 promoter methylation is associated mainly with the P210 form of BCR-ABL and not the P190 form. While six out of the seven P210-positive ALL samples had ABL1 promoter methylation, none of the 11 P190-positive ALL samples demonstrated ABL1 promoter methylation. In addition, we estimated the extent and relative abundance of ABL1 promoter methylation in several Ph-positive ALL samples and compared it to the methylation pattern in chronic, accelerated and blastic crisis phases of CML. We put forth a model that correlates the different types of leukemias with the different levels of ABL1 promoter methylation.
引用
收藏
页码:575 / 582
页数:8
相关论文
共 50 条
  • [31] Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph plus ALL patient
    Cullot, Gregoire
    Lagarde, Valerie
    Cayuela, Jean-Michel
    Prouzet-Mauleon, Valerie
    Turcq, Beatrice
    Hicheri, Yosr
    Roy, Lydia
    Braun, Thorsten
    Mozziconacci, Marie-Joelle
    Alary, Anne-Sophie
    Dulucq, Stephanie
    ANNALS OF HEMATOLOGY, 2025, : 1117 - 1126
  • [32] Expression of BCR/ABL p210 from a Knockin Allele Enhances Bone Marrow Engraftment without Inducing Neoplasia
    Foley, Samantha B.
    Hildenbrand, Zacariah L.
    Soyombo, Abigail A.
    Magee, Jeffery A.
    Wu, Yipin
    Oravecz-Wilson, Katherine I.
    Ross, Theodora S.
    CELL REPORTS, 2013, 5 (01): : 51 - 60
  • [33] External quality assessment of p210 BCR-ABL1 transcript quantification by RT-qPCR: Findings and recommendations
    Fu, Yu
    Zhang, Rui
    Wu, Qisheng
    Zhang, Jiawei
    Bao, Lihua
    Li, Jinming
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 (01) : 46 - 54
  • [34] An unusual case of high hyperdiploid childhood ALL with cryptic BCR/ABL1 rearrangement
    Lizcova, Libuse
    Zemanova, Zuzana
    Lhotska, Halka
    Zuna, Jan
    Hovorkova, Lenka
    Mejstrikova, Ester
    Malinova, Eva
    Rabasova, Jana
    Raska, Ivan
    Sramkova, Lucie
    Stary, Jan
    Michalova, Kyra
    MOLECULAR CYTOGENETICS, 2014, 7
  • [35] BCR-ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in ph+ ALL
    Cao, Wen-bin
    Yao, Jian-feng
    Feng, Si-zhou
    He, Yi
    Jiang, Er-lie
    Zhang, Rong-li
    Yang, Dong-lin
    Gong, Ming
    Zheng, Xiao-hui
    Chen, Shu-lian
    Sun, Jia-li
    Zhou, Lu-kun
    Han, Ming-zhe
    CANCER MEDICINE, 2018, 7 (06): : 2530 - 2540
  • [36] Philadelphia negative, Bcr-Abl positive chronic myeloid leukemia associated with pure red cell aplasia
    Karti, S
    Yilmaz, M
    Sonmez, M
    Akdogan, R
    Ersoz, S
    Ucar, F
    Ovali, E
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2003, 22 (02) : 341 - 342
  • [37] PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl
    Jain, SK
    Susa, M
    Keeler, ML
    Carlesso, N
    Druker, B
    Varticovski, L
    BLOOD, 1996, 88 (05) : 1542 - 1550
  • [38] Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Kimura, Shinya
    Maekawa, Taira
    Kitahara, Toshihiko
    Tanaka, Yoko
    Ohyashiki, Kazuma
    PLOS ONE, 2014, 9 (02):
  • [39] Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells
    Massimino, Michele
    Tirro, Elena
    Stella, Stefania
    Pennisi, Maria Stella
    Vitale, Silvia Rita
    Puma, Adriana
    Romano, Chiara
    Di Gregorio, Sandra
    Romeo, Maria Anna
    Di Raimondo, Francesco
    Manzella, Livia
    IN VIVO, 2020, 34 (02): : 511 - 516
  • [40] Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone
    SS Winter
    JM Greene
    TS McConnell
    CL Willman
    Leukemia, 1999, 13 : 2007 - 2011